Novo Before Q3 Earnings: How Should Investors Play the Stock?

Ahead of its Nov. 4, 2026, Q3 report, Novo faces pressure from GLP-1 competition, pricing and weaker injectable prescription trends; consensus revenue is $11.39B and EPS is $0.81. The 2026 EPS estimate fell to $3.42 from $3.45 over the past 60 days, and Novo expects adjusted sales and operating profit to range from flat to a 6% decline at CER. Oral Wegovy and Ozempic launches and the CagriSema pipeline offer potential growth, but the article recommends investors stay on the sidelines given limited recovery visibility.

Analysis

The key debate is not whether obesity demand is large, but who captures its economics as access broadens and treatment shifts toward pills. Prescription growth is not enough: investors need evidence that oral launches add profitable demand rather than substitute for injections at lower realized prices. The critical read-through from Novo’s report is therefore U.S. volume, net pricing and mix, alongside whether management can stabilize its outlook—not headline prescription counts alone.

Eli Lilly appears better positioned to absorb price competition if its reported volume momentum persists, while pressure on Novo could also weigh on the perceived value of obesity pipelines at Viking Therapeutics and Structure Therapeutics. Those smaller developers may gain strategic relevance, but phase III execution and time to commercialization make them poor near-term hedges for incumbent share losses. Novo’s valuation discount is not a floor if forward earnings estimates continue to reset; conversely, the market may be underestimating the value of oral uptake and pipeline optionality if unit economics prove sound.

Over the next few days, the earnings gap risk argues against an oversized pre-report directional position. Over 1–3 months, U.S. net price/mix and prescription trends should determine whether the earnings reset is still underway. Over 6–18 months, CagriSema’s regulatory outcome and differentiation, plus launch economics for oral products, are more consequential than early uptake alone. A sustained recovery thesis is falsified by continued estimate cuts or weaker U.S. volume; the bearish thesis weakens if Novo stabilizes pricing and demonstrates incremental oral demand without cannibalization.

Key Decisions for Investors

• Avoid a large unhedged Novo position ahead of the Nov. 4 release. After the report, consider a modest relative-value position long Eli Lilly and short/underweight Novo only if Novo’s U.S. net pricing or volume and forward outlook disappoint; do not initiate solely on the valuation gap.
• For the pair, exit or reconsider if Novo reports sequential stabilization in U.S. volume and realized pricing, demonstrates oral sales are incremental, or raises its outlook. Also cut the long leg if Eli Lilly’s volume growth falters or price concessions materially weaken its growth profile.
• Treat oral prescription counts as an alert, not a buy signal: verify paid demand, refill persistence, net sales and mix, and whether oral products replace injectable use. If these disclosures are unavailable, keep exposure small pending follow-up data.
• Do not use Viking Therapeutics or Structure Therapeutics as near-term substitutes for Novo exposure: their potential upside is tied to clinical execution and commercialization timelines, not the incumbent’s next-quarter share shifts. Reassess on meaningful phase III efficacy, safety or regulatory milestones.